Alliance for the Family Foundation v. Garin
REITERATIONFacts
The Antecedents: The case involves petitions challenging the registration, re-certification, procurement, and administration of contraceptive drugs and devices, including Implanon and Implanon NXT, by the Department of Health (DOH) and the Food and Drug Administration (FDA). Petitioners alleged that these contraceptives were abortifacients, violating the RH Law. The Supreme Court had previously issued a Temporary Restraining Order (TRO). Procedural History: Respondents filed an Omnibus Motion seeking partial reconsideration of the August 24, 2016 Decision. The Court's prior decision remanded the case to the FDA for a hearing on whether the contraceptives were abortifacients, directed the FDA to formulate procedural rules for screening and approving contraceptives with due process requirements, and ordered the DOH to formulate rules for the purchase and distribution of contraceptives, also with due process safeguards. The contempt petition was denied. The Petition: The Omnibus Motion argued that due process, specifically notice and hearing, was not required for the FDA's actions as they were performed in the exercise of its regulatory powers, not quasi-judicial powers. Respondents also contended that the Ang Tibay v. CIR standards were inapplicable and that the TRO caused undue delay and potential stockouts of family planning supplies.
Issue(s)
Whether the FDA's actions in registering, re-certifying, procuring, and administering contraceptive drugs and devices, performed in the exercise of its regulatory powers, are exempt from the requirements of due process. Whether the standards of procedural due process laid down in Ang Tibay v. CIR are applicable to the FDA's certification proceedings for contraceptive drugs and devices. Whether the petitioners were denied their constitutional right to due process. Whether the Court has the competence to review the findings of the FDA on the non-abortifacient character of contraceptive drugs or devices. Whether the Temporary Restraining Order (TRO) should be lifted.
Ruling
The Court DENIED the Omnibus Motion filed by the respondents, but MODIFIED its August 24, 2016 Decision. The FDA is ordered to consider the oppositions filed by the petitioners regarding the listed drugs, including Implanon and Implanon NXT, based on the standards of the Reproductive Health Law, as construed in Imbong v. Ochoa, and to decide the case within sixty (60) days from submission. The TRO shall be deemed lifted after the FDA's final resolution, should the questioned drugs and devices be found not abortifacients. Any appeal after the FDA's final resolution should be to the Office of the President. The FDA is also directed to amend the Implementing Rules and Regulations of R.A. No. 10354 to strictly comply with the mandates of Imbong v. Ochoa.
Ratio Decidendi
On whether the FDA's actions in its regulatory capacity are exempt from due process: The Court held that the exercise of regulatory power does not exempt an administrative agency from judicial review, especially when there is a commission of grave abuse of discretion, which includes the violation of the constitutional right to due process. The Court clarified that "enabling powers," which include regulatory functions, are a subcategory of quasi-judicial power and thus require adherence to due process. The invocation of regulatory power cannot shield the FDA from judicial scrutiny when constitutional rights are at stake. On the applicability of Ang Tibay v. CIR standards: The Court found that the standards laid down in Ang Tibay v. CIR are applicable to administrative proceedings, including those of the FDA, to ensure compliance with due process. The argument that substantial evidence, jurisdiction, or rules of evidence are inapplicable does not negate the fundamental right to be heard. The Court emphasized that due process in administrative proceedings requires a fair and reasonable opportunity to explain one's side and present evidence, even if a formal trial-type hearing is not always necessary. On the denial of petitioners' right to due process: The Court found that petitioners were indeed denied their right to due process because the FDA failed to act upon or address their oppositions regarding the abortifacient nature of the contraceptives. Instead of addressing the substantive arguments, the FDA relied on technical and procedural challenges. The Court noted that even letters seeking information were left unanswered, rendering the process a violation of constitutional rights. On the competence of the Court to review FDA findings: The Court asserted its power of judicial review over all acts where there is a commission of grave abuse of discretion, regardless of whether the agency is exercising ministerial, quasi-judicial, or regulatory power. The presence of scientific matters does not oust the courts of jurisdiction. The Court can review FDA findings to ensure compliance with constitutional mandates, particularly due process. On the prayer to lift the TRO: The Court denied the prayer to lift the TRO, deeming it premature. Lifting the TRO before the FDA conducted the required summary hearing would render the hearing an exercise in futility. The Court reiterated that the injunction was specific to the contraceptives in question and did not prevent the FDA from testing other products. The respondents were blamed for the delay by returning to the Court instead of complying with the order to conduct a hearing.
Main Doctrine
The exercise of regulatory power by administrative agencies does not exempt them from the constitutional mandate of due process, particularly when such exercise involves the potential deprivation of rights or the determination of matters with significant public impact, such as the certification of contraceptive drugs and devices.